75%Confidence
0Views
FDASource
2026-04-06Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets reveals potential supply chain vulnerabilities in blister packaging operations that could affect patient medication integrity. This may necessitate increased quality checks for blister-packed pharmaceuticals across the industry.
Actionable: Review packaging quality controls for blister-packed medications in your portfolio.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now